Evaluation and regulatory policy: tissue-engineered technologies in healthcare systems Alex Faulkner, Cardiff Institute of Society Health & Ethics (CISHE)

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

Areas of Research Specific issues. Clinical Trials Phase I First use in humans of an experimental drug or treatment In a small group of healthy volunteers.
Long Term Care Provider Associations Meeting Sharon White CMS – Region V August 22, 2007 F314 – Pressure Ulcers.
Diabetic Foot Problems
Donor breast milk banks Implementing NICE guidance 2010 NICE clinical guideline 93.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Regulatory Framework Leigh Shaw, Director.
REGENERATIVE MEDICINE
Antibiotics Fact or Fiction Quiz
Ortec International, Inc. Developing Innovative Products To Advance Regenerative Medicine.
1 Pressure Ulcers: Stages and ICD-9 Coding Joanne Lynn, MD Quality Measurement & Health Assessment Group Office of Clinical Standards and Quality Centers.
Coding for Wound Care in 2007: Update and Changes Lawrence A. Santi, DPM APMA Coding Committee Member Brooklyn, NY
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
International Conference on Human Rights and Biomedicine Rotterdam, The Netherlands, December 2008 Clinical Trials Different types of medical research.
S ocial scientists are interested in how different innovative medical technologies including human tissue engineered products (HTEPs) fit into the changing.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
Tissue Engineering By: Cassie Kuchta & Tim Rohman.
What Do Toxicologists Do?
Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics.
Emerging Forms of Evidence in Assessing Regenerative Medicine Linda F. Hogle,Ph.D. Dept. Medical History and Bioethics University of Wisconsin School.
Drug Discovery Process
Clinical Trials The Way We Make Progress Against Disease.
Michael Stacey、Vincent Falanga ect.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Artificial Skin Vi Tran Section 1 October 23,2013 Vi Tran BME 281.
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
European Parliament Advanced Therapies Hearing May 11, 2006 Advanced Therapies The proposed EU regulation from the viewpoint of a Pharmaceutical company.
Nouaying Kue BME 281.  Dermagraft ® is a dermal substitute that is a result of original human skin. It is a cell based tissue that is grown on a three.
+ Dr. Megan Rowley Consultant in Transfusion Medicine Blood Transfusion.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Ensuring Product Quality in Gene Transfer Clinical Trials
Organogenesis Canton, MA Since 1985 First company to gain FDA approval for a “living skin” product: Apligraf® Approved for treatment of diabetic foot ulcers.
Health Biotechnology Stem Cell Therapeutics; Tissue Engineering LECTURE 21: Biotechnology; 3 Credit hours Atta-ur-Rahman School of Applied Biosciences.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
Richard J. Martin 1,2, Alison M. Chisholm 2 & David Price 2,3 1. National Jewish Health, Denver, Colorado 2. Respiratory Effectiveness Group, Cambridge,
Wounds Research for Patient Benefit funded by the.
Evidence based healthcare in the UK – any signs of life? Carl Thompson RN; PhD Editor: Evidence Based Nursing ebn.bmj.com.
Artificial Tendon Artificial Skin Artificial Ligament Artificial Cornea Soft Tissues Implants Different Products Constitute This Sector Cosmetic Lens.
1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
Proposed algorithm for approval of human TSE tests in Europe.
Oocyte Procurement Risks Ovarian hyperstimulation syndrome Ovarian hyperstimulation syndrome Ovarian torsion Ovarian torsion Hospitalization (1% or.
Biosimilars Where Are We Now? Where Are We Going? Sheldon Bradshaw January 24, 2008.
EXPERIMENTAL EPIDEMIOLOGY
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
2nd Concertation Meeting Brussels, September 8, 2011 Reinhard Prior, Scientific Coordinator, HIM Evidence in telemedicine: a literature review.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Regenerative Medicine Regenerative medicine~ Goal: to grow replacement tissue or organs for patients who have sustained an injury or have a disease that.
Presentation Developed for the Academy of Managed Care Pharmacy
Neglecting a Pressure Ulcer The consequences could result in damaging deeper layers of tissue, damage to muscle and bone (Fig 1 illustrates a grade 4 pressure.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Shaping the Future 9 th October 2012 Understanding the Financial Context Reg Middleton Chief Financial Officer West Kent Clinical Commissioning Group.
The transdermal route of delivery has increased in popularity over the past decade with a wide range of medicines now being available [1]. However with.
CLINICAL TRIALS.
Off-label Use.
Long Term Care Provider
Guidance for review of studies involving HCT/Ps and IND Basics
Evidence-based Medicine
Clinical Trials — A Closer Look
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Tissue Engineering.
Scientific Drivers Technology in Development Issues Viral vectors
Realizing effective health technology assessment for the SA healthcare environment Praneet Valodia The BHF Southern African Conference July’07.
Presentation transcript:

Evaluation and regulatory policy: tissue-engineered technologies in healthcare systems Alex Faulkner, Cardiff Institute of Society Health & Ethics (CISHE) Cardiff University, UK Julie Kent (University West of England); Ingrid Geesink (CISHE); David FitzPatrick (University College Dublin) HTAi Rome, June 2005 ESRC IHT support

Questions What forms of evaluation are used and needed for hybrid, combination technologies such as ‘human-derived therapeutic products’? What forms of evaluation are used and needed for hybrid, combination technologies such as ‘human-derived therapeutic products’? How do TE technologies affect evaluative regulatory policy and healthcare practice ? How do TE technologies affect evaluative regulatory policy and healthcare practice ?

Regulatory evaluation Evaluation of ‘risks’ & ‘benefits’ clinically and societally complex, new hazards non- predictable Evaluation of ‘risks’ & ‘benefits’ clinically and societally complex, new hazards non- predictable Regulatory policy includes representations of (‘evaluation’ of) social values & ethics Regulatory policy includes representations of (‘evaluation’ of) social values & ethics Rules of evidence/evaluation contested, negotiable, uncertain and changeable Rules of evidence/evaluation contested, negotiable, uncertain and changeable

Domains of regulatory evaluation Safety & quality (technology) Safety & quality (technology) Efficacy/effectiveness (system) Efficacy/effectiveness (system) Other values – ‘social shaping’/ acceptability (system, society) Other values – ‘social shaping’/ acceptability (system, society) Device Pharmaceutical Biologic TE?

One definition of TE technology “The use of living cells, together with either natural or synthetic extracellular components, in the development of implantable parts or devices for the restoration or replacement of function”

Combining TE materials Viable human cells or tissue e.g. chondrocytes Viable human cells or tissue e.g. chondrocytes Growth factors Growth factors Cell culture materials – human serum, bovine and/or murine cells Cell culture materials – human serum, bovine and/or murine cells Manufactured biomaterials e.g. polymer scaffolds Manufactured biomaterials e.g. polymer scaffolds Single OR multiple recipient products Single OR multiple recipient products

Skin system: Apligraf ®

Apligraf ® skin system - safety Composition ‘APLIGRAF is supplied as a living, bi-layered skin substitute. † Like human skin, APLIGRAF consists of living cells and structural proteins. The lower dermal layer combines bovine type 1 collagen and human fibroblasts (dermal cells), which produce additional matrix proteins…...’ Composition ‘APLIGRAF is supplied as a living, bi-layered skin substitute. † Like human skin, APLIGRAF consists of living cells and structural proteins. The lower dermal layer combines bovine type 1 collagen and human fibroblasts (dermal cells), which produce additional matrix proteins…...’ Safety testing The mother’s blood and donor’s cells are thoroughly screened and found negative for pathogens and other contaminants. The working cell banks are then further screened to help ensure product safety. Safety testing The mother’s blood and donor’s cells are thoroughly screened and found negative for pathogens and other contaminants. The working cell banks are then further screened to help ensure product safety. The persistence of Apligraf cells on the wound and the safety of this device in venous ulcer patients beyond 1 year and in diabetic foot ulcer patients beyond six months has not been evaluated. Source: Organogenesis Inc. website 2003 The persistence of Apligraf cells on the wound and the safety of this device in venous ulcer patients beyond 1 year and in diabetic foot ulcer patients beyond six months has not been evaluated. Source: Organogenesis Inc. website 2003

Cost effectiveness ‘Apligraf plus ‘good wound care’ treatment result in 12% reduction in cost over one year vs. gwc only’* ‘Apligraf plus ‘good wound care’ treatment result in 12% reduction in cost over one year vs. gwc only’* TE for wounds: ‘still weak scientific basis for the cost- effectiveness of TE treatments for skin TE for wounds: ‘still weak scientific basis for the cost- effectiveness of TE treatments for skin ulcers, Apligraf seems to have proven effectiveness’.** (MEDLINE, Cochrane Library, NHS Centre for Reviews and Dissemination, German Agency for HTA). *Redekop et al in Pharmacoeconomics 2003 (Inst. For Med, Technol Assessment, Rotterdam) ** Bührlen & Hüsing, Fraunhofer Institute for EC JRC-IPTS, 2003

HTA effectiveness (+safety?) – Cochrane review Headline: ‘bilayer artificial skin, used in conjunction with compression bandaging, increases the chance of healing a venous ulcer compared with compression and a simple dressing’. (2 RCTs) Headline: ‘bilayer artificial skin, used in conjunction with compression bandaging, increases the chance of healing a venous ulcer compared with compression and a simple dressing’. (2 RCTs) Noted-in-passing: ‘The most serious concern with allogeneic skin is the possibility of transmission of infection, particularly of the human immunodeficiency virus (HIV) or hepatitis. Even with rigorous screening it is still possible that skin could be harvested from an HIV- infected but seronegative donor’. (Jones and Nelson, Skin grafting for venous leg ulcers, Cochrane Library 2000) Noted-in-passing: ‘The most serious concern with allogeneic skin is the possibility of transmission of infection, particularly of the human immunodeficiency virus (HIV) or hepatitis. Even with rigorous screening it is still possible that skin could be harvested from an HIV- infected but seronegative donor’. (Jones and Nelson, Skin grafting for venous leg ulcers, Cochrane Library 2000)

Challenges to evaluation: device or pharmaceutical or TE? ‘..In the US Apligraf was seen as a device…the only issue was to prove the product was not contaminated..unlike medicinal products there was no need to demonstrate safety, no toxicology testing or evidence of efficacy was needed…In April 2001 there was the BSE scare and Germany put pressure on the EMEA to see Apligraf as a medicinal product…the product is very complex….. company had to define and devise tests for the product and then test it’ (M-EU6, 2003)

device or pharmaceutical or TE…..or xenotransplant? ‘hTEPs containing not intentionally small quantities or traces of material of animal origin (used during the manufacturing process) which do not perform any function in the finished product are not, for the purpose of this regulation, regarded as xenogenic products.’ (EuropaBio et al 2004) ‘hTEPs containing not intentionally small quantities or traces of material of animal origin (used during the manufacturing process) which do not perform any function in the finished product are not, for the purpose of this regulation, regarded as xenogenic products.’ (EuropaBio et al 2004)

Challenges to evaluation – safety and effectiveness ‘….(question) whether RCTs are, in fact, always the “gold standard” of evidence. This appears to be an appropriate time to explore the extent to which surface characterization measurements, bench-top experiments, gene expression measurements, and/or simulation can be effectively extrapolated to confidently assess safety and effectiveness’. (MTLF, 2002)

Challenges to evaluation - safety of TE technologies Requirements for: New assays New assays Nontraditonal animal models – eg transgenic animals, larger - but statistical problems Nontraditonal animal models – eg transgenic animals, larger - but statistical problems Testability problems (short shelflife) Testability problems (short shelflife) New endpoints eg genotoxicity, immunogenicity New endpoints eg genotoxicity, immunogenicity (Regulator/industry forum 2003)

Challenges to evaluation – social shaping/acceptability “Currently, consent is not obtained when biological products (including allografts and xenografts) are applied to patients belonging to diverse religious and cultural backgrounds. Furthermore, the awareness of the healthcare professionals about the constituents of biological products has never been evaluated nor whether they have the necessary knowledge to obtain informed consent from patients being treated with such material”. Enoch S, Shaaban H and Dunn KW. Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material J Med Ethics 2005;31:2-6.

contd…….. Enoch et al survey results for specialist healthcare professionals (n=100, multi-sites, UK): contd…….. Enoch et al survey results for specialist healthcare professionals (n=100, multi-sites, UK): Product includes ‘pig’ or ‘cow’ biol.material Applica- tion % “don’t know” % “don’t know” Apligraf burns, ulcers 68% Biobrane biol. dressing 57% Integraburns30% Allodermburns74%

Conclusions Tissue sourcing evaluable for safety and social shaping/acceptability, not HTA Tissue sourcing evaluable for safety and social shaping/acceptability, not HTA ‘Social shaping’, acceptability, ‘consent’ ‘Social shaping’, acceptability, ‘consent’ More social values assessment – complexity of healthcare delivery More social values assessment – complexity of healthcare delivery Trials as a route to ‘approval’ Trials as a route to ‘approval’ Separability of evaluation domains? - pressure of material technology regulatory framing, social meanings Separability of evaluation domains? - pressure of material technology regulatory framing, social meanings